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In this issue of Cancer Cell, Sturm et al. report that global DNA methylation patterns in glioblastoma multi-
forme divide adult and pediatric tumors into subgroups that have characteristic DNA mutations, mRNA
profiles, and most importantly, different clinical behaviors. These findings suggest novel opportunities for
therapeutics for this dreaded disease.Glioblastoma multiforme (GBM) is the
most aggressive brain tumor and is asso-
ciated with very poor overall survival.
GBM occurs in adults much more fre-
quently than in children or adolescents,
and pediatric GBM has genetic abnormal-
ities that make it distinct from adult
tumors, suggesting that although the
microscopic appearance and grim prog-
nosis are shared (Figure 1), pediatric and
adult GBM have different underlying biol-
ogies (Paugh et al., 2010). In this issue of
Cancer Cell, Sturm et al. (2012) show that
pediatric GBM contains two epigenetic
subgroups that are distinct from those
found in adult tumors. The epigenetic
profiles of these groups correlate tightly
with mutations in H3F3A. This gene
encodes the replication-independent his-
tone H3.3, which predominantly binds
transcriptionally active loci and telomeres.
H3.3 is frequentlymethylatedat or near the
residues that are mutated. Alterations in
histonemethylationaffect theaccessibility
of the associated DNA and may promote
changes in DNA methylation (Turcan
et al., 2012). H3F3A mutations therefore
provide a potential mechanism underlying
the global methylation changes observed
in these pediatric GBM subgroups.
These findings build on earlier studies
that showed that adult GBM could be
subdivided into three epigenetic sub-
groups, one of which correlated with
mutations in the metabolic gene IDH1
(Noushmehr et al., 2010; Parsons et al.,
2008; Verhaak et al., 2010). Patients
without IDH1 mutation are older and
have more rapidly progressive disease,
whereas those with IDH1 mutation
frequently have an antecedent low gradeglioma, are younger, have more frequent
TP53 mutations, and are less likely to
have receptor tyrosine kinase amplifica-
tion (Parsons et al., 2008). The IDH1
mutation is a gain of function alteration
that creates a novel onco-metabolite, 2-
hydroxyglutarate (2HG), which interferes
with the normal cellular methylation
machinery. This in turn leads to wide-
spread increases in global methylation
known as the CpG-island methylator
phenotype (CIMP) (Turcan et al., 2012).
mRNA expression profiling identified four
subgroups of adult GBM (proneural,
neural, classical, and mesenchymal) and
determined that each subgroup contains
distinct pathway alterations (Verhaak
et al., 2010). Tumors with IDH1mutations
fall primarily into the proneural expression
profile, and in epigenetic analyses, CIMP+
tumors segregate into that same group
(Noushmehr et al., 2010).
IDH1 is rarely altered in pediatric
GBMs. Indeed, pediatric GBM contain
significantly different genomic alterations
from adult tumors (Paugh et al., 2010).
The recent discovery that mutations in
the histone gene H3F3A occur predomi-
nantly in pediatric high grade gliomas
(Schwartzentruber et al., 2012) further
emphasizes the differences between
adult and pediatric GBM. Sturm et al.
(2012) now show that an expanded anal-
ysis of the methylome of GBM, which
includes pediatric GBM cases, can divide
this tumor into six subgroups, two of
which are primarily pediatric, and the
remainder of which are primarily adult.
Methylation groups largely correlate with
the pattern of expression profiling that
was previously reported, emphasizingCancer Cell 22the importance of epigenetic regulation
in GBM (Verhaak et al., 2010).
Sturm et al. (2012) show that three of
the epigenetic subgroups (two pediatric
and one adult) correlate with mutations
in H3F3A and IDH1. H3F3A and IDH1
mutations are non-overlapping, sug-
gesting that they represent different paths
to achieve widespread alterations in
genomic methylation. The two mutations
in H3F3A are seven amino acid residues
apart and are associated with dramati-
cally different methylation profiles. The
H3F3A G34 mutation is associated with
a hypomethylation phenotype, which is
most prominent at the ends of chromo-
somes. The H3F3A K27 mutation is asso-
ciated with a methylation pattern that is
distinct from both that of H3F3A G34
and the CIMP+ phenotype associated
with IDH1 mutation.
There is also increasing evidence that
alterations in H3F3A and IDH1 interfere
with the normal differentiation of neural
progenitors. The abnormal metabolite
2HG produced by mutant IDH1 leads
to increased repressive methylation at
H3K27 and inhibits immortalized neural
cell differentiation, suggesting a potential
common mechanism for tumorigenesis
in IDH1 and H3F3A K27M mutant groups
(Lu et al., 2012). IDH1mutation also leads
to increased neural stem cell marker
expression and decreased expression of
mature differentiation genes in response
to differentiation signals, which are hall-
marks of pre-cancerous cells (Turcan
et al., 2012). Sturm et al. (2012) show in
H3F3A G34 mutated glioblastoma a
similar decrease in expression of OLIG2,
an important neuro-developmental gene., October 16, 2012 ª2012 Elsevier Inc. 417
Figure 1. Similar Appearances, Different Methylomes, and
Divergent Outcomes
A pediatric midline GBM of the pons (a diffuse intrinsic pontine glioma,
left) and a hemispheric glioblastoma multiforme arising in a young adult
(right) have a similar histologic appearance on high power hematoxylin and
eosin photomicrographs. Yet, as demonstrated by Sturm et al. (2012) in this
issue of Cancer Cell, these two tumors affect different patient populations,
arise in anatomically distinct regions, have different methylation profiles,
and behave differently. For both images, magnification = 2003 and scale
bar = 100 mM.
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PreviewsLoss of OLIG2 is associated
with increased methylation
at the OLIG2 locus, which
occurs despite the global hy-
pomethylation of the genome
in H3F3A G34 mutated glio-
blastoma. Although there
are intriguing similarities in
the pathways between IDH1
and H3F3Amutated glioblas-
toma, the disparate methyla-
tion signatures and clinical
course of these three groups
involving children and young
adults suggest that the
mechanism by which these
alterations lead to transfor-
mation of normal cells will
require extensive study.
Although this study shows
that different GBM meth-
ylation subgroups have
somewhat variable clinical
courses, the overall out-
comes of children and adults
with GBM is extremely poor,with few long-term survivors reported
in the literature (Louis et al., 2007). It
remains to be seen how identification of
methylation alterations will translate into
improved therapeutic options for these
patients. The significant changes in
global methylation patterns identified by
Sturm et al. (2012) make epigenetic
altering agents an attractive therapeutic
modality. The Children’s Oncology Group
is currently investigating altering chro-
matin structure with histone deacetylase
inhibitors in GBM (NCT01236560). How-
ever demethylating agents have not
been widely investigated in pediatric
GBM.
Sturm et al. (2012) show that the
G34 subgroup of pediatric GBM is418 Cancer Cell 22, October 16, 2012 ª2012hypomethylated preferentially at the
chromosome ends and features the
alternative lengthening of telomeres
(ALT) phenotype. Although the precise
mechanism of ALT remains unknown,
the presence of promyelocytic leukemia
bodies and evidence of heterologous
recombination between telomeres pro-
vide enticing targets for therapy (Heaphy
et al., 2011). The recent increases in our
understanding of the genetics of GBM,
and in particular, the integration of
both pediatric and adult tumors into an
overall epigenomic classification scheme
by Sturm et al. (2012), set the stage for
translation of molecular advances into
improved care for patients with this
disease.Elsevier Inc.REFERENCES
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